FDA Now Requires Blindness Risk Warning on GLP-1 Weight Loss Drugs

The new label requirement places a formal regulatory burden on manufacturers of some of the most widely prescribed medications in the United States, and signals that post-market surveillance...

The U.S. Food and Drug Administration has required manufacturers of GLP-1 receptor agonist medications, including semaglutide products sold as Ozempic and Wegovy and tirzepatide products sold as Mounjaro and Zepbound, to add warnings about a potentially serious eye condition to their drug labels, according to a report published by The Hill on November 12, 2026. The Hill

The eye condition at issue is non-arteritic anterior ischemic optic neuropathy, commonly abbreviated NAION. The condition involves a reduction in blood flow to the optic nerve and can result in permanent, partial, or complete vision loss in the affected eye. NAION is considered a stroke of the optic nerve by some clinicians and has no established treatment that reliably restores vision once it occurs.

GLP-1 medications work by mimicking the glucagon-like peptide-1 hormone, which stimulates insulin release and suppresses appetite. The class of drugs has seen rapid adoption since semaglutide received FDA approval for type 2 diabetes management in 2017 and for chronic weight management in 2021. Manufacturer Novo Nordisk reported global net sales of Ozempic and Wegovy combined at approximately 232.3 billion Danish kroner for full-year 2024, according to the company's publicly filed annual report. Eli Lilly, maker of Mounjaro and Zepbound, reported combined revenue for those products exceeding $11.5 billion in 2024, per the company's Form 10-K filed with the Securities and Exchange Commission.

The FDA's label change requirement follows a process governed under 21 CFR Part 201, which outlines the agency's authority to require manufacturers to revise drug labeling when new safety information emerges from post-market data, clinical studies, or adverse event reports submitted through the FDA's MedWatch system. The agency's Adverse Event Reporting System, known as FAERS, is a public database where such reports are catalogued and are accessible for independent review.

A study published in JAMA Ophthalmology in July 2024 by researchers at Massachusetts Eye and Ear found that patients taking semaglutide for type 2 diabetes or obesity had a statistically elevated risk of NAION compared to patients taking other medications for the same conditions. That study examined a retrospective cohort of 16,827 patients. The researchers noted the association warranted further investigation but did not establish a proven causal mechanism.

The FDA's decision to mandate label updates does not constitute a recall or a market withdrawal. The agency's action places an obligation on manufacturers to communicate the identified risk to prescribing physicians and patients. Under the agency's regulations at 21 CFR 201.57, the warning section of a prescription drug label must describe clinically significant adverse reactions and other potential safety hazards.

Physicians who prescribe GLP-1 medications are now required to counsel patients on the NAION risk as part of the informed consent process. Patients who have a prior history of NAION in one eye face a higher baseline risk of experiencing the condition in the second eye, according to the American Academy of Ophthalmology's clinical guidance, which predates the current FDA action.

The label change affects millions of current users. The CDC's National Center for Health Statistics estimated in 2024 data that approximately 42.4 percent of U.S. Adults meet the clinical definition of obesity, the population for which Wegovy and Zepbound carry approved indications. GLP-1 prescriptions in the United States increased more than 300 percent between 2020 and 2023, according to IQVIA Institute data cited in a 2024 Department of Health and Human Services report.

Congress has taken legislative interest in the GLP-1 market, primarily around Medicare and Medicaid coverage. The Treat and Reduce Obesity Act, reintroduced in the 119th Congress as H.R. 4818 per the congressional record, would require Medicare Part D plans to cover FDA-approved obesity medications including GLP-1 drugs. The bill had not received a floor vote as of the date of this publication.

What remains unknown is the specific incidence rate the FDA used to trigger the mandatory labeling action, as the agency has not yet published the full safety review document that underpins its decision. That document would typically appear in the FDA's online Drugs@FDA database under the new drug application records for each affected product, and its release would allow independent researchers and clinicians to assess the magnitude of the risk the agency quantified.